These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 597607)

  • 21. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
    Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
    Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of primary and metastatic tumor growth in mice by cancer-associated galactosyltransferase acceptor.
    Podolsky DK; Carter EA; Isselbacher KJ
    Cancer Res; 1983 Sep; 43(9):4026-30. PubMed ID: 6409394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of 1-nitro-9-aminoacridines including nitracrine against some ascitic experimental tumors.
    Mazerska Z; Lukowicz J; Konopa J
    Arzneimittelforschung; 1990 Apr; 40(4):472-7. PubMed ID: 2357249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Characteristics in antitumor effects of organic silicon related compounds].
    Fukushima K
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2173-81. PubMed ID: 2544147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
    Bartik MM; Takesue BY; Mokyr MB
    Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Blastolysin, an agent potentiating the antitumor action of ionizing radiation].
    Iarmonenko SP; Syrkin AB; Treshchalin ID
    Dokl Akad Nauk SSSR; 1980; 253(6):1495-9. PubMed ID: 7428605
    [No Abstract]   [Full Text] [Related]  

  • 27. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effect of N alpha-benzyloxycarbonyl-N,N-bis-(2-halogenethyl)-hydrazide derivatives of amino acids.
    Karaivanova MH; Zakhariev SG; Golovinsky EV
    Neoplasma; 1980; 27(2):137-42. PubMed ID: 7393353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Change in the natural immunity of mice after administration of blastolysin, a glycopeptide from the Lactobacillus bulgaricus cell wall].
    Shepeleva IB; Zakharova NS; Remova TN; Bazhanova IG; Sorokina IB
    Antibiot Med Biotekhnol; 1985 Jun; 30(6):442-6. PubMed ID: 2998270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
    Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
    Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Embryonal mass and hormone-associated effects of pregnancy inducing a differential growth of four murine tumors.
    Bustuoabad OD; di Gianni PD; Franco M; Kordon EC; Vanzulli SI; Meiss RP; Grion LC; Díaz GS; Nosetto SH; Hockl P; Lombardi MG; Pasqualini CD; Ruggiero RA
    Oncol Res; 2002; 13(3):147-60. PubMed ID: 12549624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antitumor activity and toxicity of KB-5424 R, a newly developed antitumor platinum compound].
    Yamaguchi H; Kubota T; Takahara T; Takeuchi T; Furukawa T; Kase S; Josui K; Kodaira S; Ishibiki K; Abe O
    Gan To Kagaku Ryoho; 1991 Jun; 18(7):1135-41. PubMed ID: 2053772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
    Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
    Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The antineoplastic activity of testiphenon].
    Lagova ND; Sof'ina ZP; Shkodinskaia EN; Kurdiumova KN; Valueva IM
    Vopr Onkol; 1988; 34(11):1363-8. PubMed ID: 3201773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of blastolysin on the development of specific immunity to whooping cough].
    Shepeleva IB; Zakharova NS; Remova TN; Bazhanova IG; Britsina MV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Jan; (1):62-5. PubMed ID: 3705806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
    Hornung RL; Pearson JW; Beckwith M; Longo DL
    Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.